Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Entera Bio ( (ENTX) ) just unveiled an announcement.
Entera Bio Ltd., a leader in oral peptide development, reported Q3 2024 financial results and business updates, highlighting advancements in their oral PTH(1-34) tablet, EB613, for osteoporosis. The company is anticipating a pivotal FDA ruling on osteoporosis drugs, which could enhance their treatment’s standing. Entera is also progressing with other oral therapies, like GLP-1/glucagon for obesity and GLP-2 for short bowel syndrome, using their proprietary N-Tab™ platform. Financially, Entera reported a net loss of $3 million with sufficient cash to fund operations into Q3 2025.
See more insights into ENTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- #BoycottWalmart Gains Steam Post “No Kings” Protests, Walmart Stock (NYSE:WMT) Notches Up
- “Prices at the National Level…Stopped Falling”: iShares S&P / TSX Capped REIT Index ETF Stock (TSE:XRE) Notch Up as Home Sales Mount
- 3 “Strong Buy” Technology Stocks to Buy Now, 6/16/25, According to Top Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue